Vietnam is focusing on improving research capacity and application of new drug production technology, promoting clinical pharmacy development and strengthening supervision of safe and reasonable drug use. Vietnam is focusing on improving research capacity and application of new drug production technology, promoting clinical pharmacy development and strengthening supervision of safe and reasonable drug use, aiming
On November 28, 2023, Vietnam Evaluation Report Joint Stock Company (Vietnam Report) officially announced the Top 10 prestigious Pharmaceutical Companies in 2023. Top 10 reputable Pharmaceutical Companies are built on scientific and objective principles. Companies are evaluated and ranked based on 3 main criteria: (1) Financial capacity shown on the most recent year’s financial statements;
By Mr. Ong Van Dung, General Director, Stellapharm Stellapharm (former name was STADA-VN – a Joint Venture Pharmaceutical Company formed in 2002 with a Vietnamesecompany named M.S.T and German cooperation named STADA Arzneimittel). Stellapharm has become one of the leading generic pharmaceutical manufacturers in Vietnam, we follow the global quality standard in accordance with European
It is critical for pharmaceutical companies to improve competitiveness with a focus on research and development (R&D), production technology and digitalisation. According to experts, this will help them expand their shares in the domestic market which remains being dominated by imported drugs and extend their international reach.Vietnam’s pharmaceutical market has significant potential. The Ministry of
Despite having a good market, the pharmaceutical manufacturing in Vietnam still faces many difficulties. This difficulty comes from industry competition, world competition and technological development. In order for the pharmaceutical manufacturing to develop, what should pharmaceutical enterprises do? Overview of Vietnam’s pharmaceutical manufacturing industry 2023.The market for the pharmaceutical industry in Vietnam is relatively active:The
As one of seven generic drug manufacturers selected by MPP and becoming a sub-licensee of Shionogi – a Japanese pharmaceutical manufacturer to produce of XOCOVA™ drug, generic version. Stellapharm is honored and proud to have contributed to repelling the COVID-19 pandemic with drugs. This is the third oral product in the world to be recognized
What is prediabetes? Prediabetes is a serious health condition where blood sugar levels are higher than normal, but not high enough yet to be diagnosed as type 2 diabetes. Approximately 96 million American adults – more than 1 in 3 – have prediabetes. Of those with prediabetes, more than 80% don’t know they have it.
Lesovir is manufactured by its EU-GMP facility and distributed via exclusive distributor, Khuong Duy Pharma Co., Ltd.
On February 21, 2022, Stellapharm officially signed a contract with MPP (Medicines Patent Pool), a UNITED NATIONS-backed public health organization to become the only manufacturer in Vietnam allowed to produce a generic version of Pfizer’s oral COVID-19 treatment, nirmatrelvir, which will be co-packaged with ritonavir, under the voluntary licensing agreement between Pfizer and the MPP.
HÀ NỘI — The Drug Administration of Việt Nam under the Ministry of Health has issued the list of three COVID-19 treatment drugs produced in Việt Nam that contain the antiviral ingredient Molnupiravir, which have been granted certificates of registration for conditional use. The three products – Molravir 400mg produced by Boston Việt Nam Pharma (based in
The antiviral was found to be safe and effective following a stringent review of the available evidence. The antiviral Lagevrio (molnupiravir) is safe and effective at reducing the risk of hospitalisation and death in people with mild to moderate COVID-19 who are at increased risk of developing severe disease, the Medicines and Healthcare products Regulatory
20 January 2022 Geneva – The Medicines Patent Pool (MPP) announced today that it has signed agreements with 27 generic manufacturing companies for the manufacturing of the oral COVID-19 antiviral medication molnupiravir and supply in 105 low- and-middle-income countries (LMICs). The sublicence agreements are the result of the voluntary licensing agreement signed by MPP and
Since the beginning of February this year, many consignments of Stella's pharmaceutical products with a total of nearly 200 million units have been urgently exported by air to markets in Germany, France, Austria, Belgium, Ireland, etc.
In brief, an allergy is an unusual or exaggerated immune response triggered by a particular substance. Symptoms often include itchy eyes, wheezing, and sneezing. For many people, allergic reactions are uncomfortable and unpleasant, but they can be life-threatening for others. According to estimates from the Centers for Disease Control and Prevention (CDC), up to 60
A novel coronavirus, originally identified in Wuhan City, China, was reported to the World Health Organization on 31 December 2019, and the associated disease has subsequently become a worldwide pandemic. An effective antiviral therapeutic has since been intensively sought. Coronaviruses use an RNA-dependent RNA polymerase (RdRp) for the replication and transcription of their RNA genome.
On January 10, 2022, Stellapharm officially signed an agreement with MPP (Medicines Patent Pool), a UNITED NATIONS-backed public health organization to become the only manufacturer in Vietnam allowed to produce the COVID-19 treatment molnupiravir under the "Voluntary Licensing" program for MSD, a trade name of Merck & Co., Inc., Kenilworth, NJ, USA.
This will be the first steroid-hormone pharmaceutical factory in Vietnam and among a few ASEAN factories built in compliance with European Standards for this line of products.
“Accrediting the fifth EU-GMP is one of our commitment on maintaining highest EU standards and quality of products with affordable prices” said by Choo Yan Ho, the Chairman.
On 15 March 2016, the fourth EU-GMP Inspection was conducted at STADA – VN J.V. Co., Ltd., Binh Duong Branch, currently known as STELLAPHARM J.V. Co., Ltd. – Branch 1
[Updated to July 2021] The results of the trial demonstrate the safety, tolerability, and antiviral efficacy of molnupiravir to reduce replication of SARS-CoV-2 and accelerate clearance of infectious virus and support ongoing trials of molnupiravir to prevent progression of COVID-19 and eliminate onward transmission of SARS-CoV-2. After more than one year into the coronavirus disease
On 06 January 2015, STADA – VN J.V. Co., Ltd., Binh Duong Branch (the “STELLA” or “Factory II“), was appreciated by Ministry of Health, Labour and Welfare (the "MHLW") issued the certificate of Japan GMP for the product of Soleton 80 with its composition and strength: Zaltoprofen 80 mg
STADA - VN JOINT VENTURE CO., LTD. officially changed its name to STELLAPHARM J.V. CO., LTD. since 16 August 2019.
On 19 March 2013, the third EU-GMP Inspection was conducted in five continuous days at STADA – VN J.V. Co., Ltd., Binh Duong Branch (the “Company” or “Factory II“), located at Vietnam – Singapore Industrial Park, Binh Duong and the Factory II was recognized as a pharma facility complying with European Good Manufacturing Practice issued
According to the World Health Organization, obesity rates have tripled worldwide since 1975. The connection between obesity and insulin resistance is bidirectional. Insulin resistance often develops due to being overweight or obese, which can lead to type 2 diabetes. Since type 2 diabetes can be a costly disease to treat, contribute to many health issues,
in December 23, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Merck’s molnupiravir for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom
By Stephanie NolenOct. 17, 2021 Merck has taken a step to make its antiviral pill available in poor nations, but many obstacles remain for broad access to coronavirus drugs. Nearly a year after the first Covid-19 vaccination campaigns began, the vast majority of the shots have gone to people in wealthy nations, with no clear